NCT00373347Completed
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 17 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 573 (actual)
- First submitted
- 6 Sept 2006
- Start date
- Nov 2004
- Primary completion date
- 18 Nov 2024
- Lead sponsor
- Stanford University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT00373347
What you commit to
- Study type: Observational
- Participants enrolled: 573
- From Nov 2004 to the primary completion date, 18 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- -Patients will be excluded if, upon looking through their medical records, information required for data analysis are missing.
Who the study is looking for
- Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI.
- Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia.
- Patients with hepatitis B or hepatitis C viral infections not associated with liver cancer.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stanford University School of Medicine Coordinator of this site? Confirm its status | Stanford | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.